Navigation Links
Cardica Announces Fiscal 2009 First Quarter Financial Results

- PAS-Port(R) Proximal Anastomosis System Received 510(k) Clearance from

U.S. Food and Drug Administration (FDA) - - Development Progress Triggered $1M Milestone Payment from Cook Medical -

- Conference Call Today at 4:30 p.m. Eastern Time -

REDWOOD CITY, Calif., October 28 /PRNewswire-FirstCall/ -- Cardica, Inc. (Nasdaq: CRDC) today reported financial results and corporate progress for its fiscal 2009 first quarter ended September 30, 2008.

"We had an excellent quarter with the FDA clearance of our PAS-Port(R) Proximal Anastomosis System for use in coronary artery bypass graft (CABG) procedures, a pivotal event for Cardica and, we believe, the field of cardiothoracic surgery," said Bernard A. Hausen, M.D., Ph.D., president and chief executive officer of Cardica. "We trained 30 surgeons in September to use the PAS-Port system, and it has been used in numerous CABG surgeries throughout the United States, including in several total connector CABG cases, in which our C-Port and PAS-Port automated systems are used to connect all bypass grafts, eliminating the need to hand sew any of the vessels."

"We continue to train physicians on the use and benefits of our C-Port(R) Distal Anastomosis Systems. We also are pleased to report that our collaborations with Cook Medical are proceeding on track, and we are looking toward the launch of the Cook Vascular Access Closure Device (CVCD) in Europe," continued Dr. Hausen.

Commercial Accomplishments

-- Received 510(k) clearance from the FDA for the PAS-Port(R) Proximal Anastomosis System in September;

-- Trained a total of 358 surgeons on the C-Port(R) Distal Anastomosis Systems since product introduction, and 30 U.S. surgeons on the PAS-Port system since FDA clearance;

-- Increased cumulative worldwide shipments of C-Port systems to over 7,000 units, with 1,017 units sold in the fiscal 2009 first quarter;

-- Increased cumulative worldwide shipments of PAS-Port systems to over 9,700 units, with 815 units sold in the fiscal 2009 first quarter and the majority of units deployed in Japan; and

-- Enabled several cardiothoracic surgeons to perform total connector coronary artery bypass, or C-CAB(TM), procedures for the first time in the United States, using only the C-Port and PAS-Port systems to attach bypass grafts.

Corporate and Development Achievements

-- Received a $1 million milestone payment from Cook Medical for the successful development of a specialized device to close holes in the heart known as patent foramen ovales;

-- Delivered CVCD devices to Cook for initial launch of the product in Europe; and

-- Appointed Frederick Bauer to the position of vice president, operations.

Fiscal 2009 First Quarter Financial Results

Total net revenue was approximately $2.1 million for the fiscal 2009 first quarter compared with $1.3 million for the fiscal 2008 first quarter. Total product revenue was approximately $1.6 million for the fiscal 2009 first quarter, compared with $1.0 million for the same period of fiscal 2008. Cost of product revenue was approximately $1.1 million for the fiscal 2009 first quarter, representing a 29 percent gross margin, compared with $1.0 million for the fiscal 2008 first quarter.

Research and development expenses were approximately $2.3 million for the fiscal 2009 first quarter compared with $1.7 million for the fiscal 2008 first quarter. Selling, general and administrative expenses for the fiscal 2009 first quarter were approximately $3.9 million compared with $2.6 million for the same period in fiscal 2008.

The net loss for the fiscal 2009 first quarter was approximately $5.2 million, or $0.33 per share, compared with a net loss of $3.7 million, or $0.27 per share, for the fiscal 2008 first quarter.

Cash and investments at September 30, 2008, were $17.6 million, compared to $23.3 million at June 30, 2008. As of September 30, 2008, there were approximately 15.8 million shares of common stock outstanding.

Updated Financial Guidance for Fiscal 2009

For fiscal 2009, Cardica expects total revenue of $14 to $17 million. Cardica expects product revenue of $12 to $14 million, with collaboration revenue of $2 to $3 million. Cardica expects to realize improving gross margin on product revenue throughout the year. Cardica continues to expect that fiscal 2009 research and development, sales, general and administrative costs will total between $26 and $28 million, including non-cash stock-based compensation expense of approximately $2 million.

Conference Call Details

To access the live conference call on October 28, 2008, at 4:30 p.m. Eastern Time via phone, please dial 866-203-3206 from the United States and Canada or 617-213-8848 internationally. The conference ID is 77165918. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through November 4, 2008, and may be accessed by dialing 888-286-8010 from the United States and Canada or 617-801-6888 internationally. The replay passcode is 11080596.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of Cardica's website at Please connect to the website at least 15 minutes prior to the call to allow for any necessary software downloads.

About Cardica, Inc.

Cardica is a leading provider of automated anastomosis systems for coronary artery bypass graft (CABG) surgery. By replacing hand-sewn sutures with easy-to-use automated systems, Cardica's products provide cardiovascular surgeons with rapid, reliable and consistently reproducible anastomoses, or connections of blood vessels, often considered the most critical aspect of the CABG procedure. Cardica's C-Port(R) Distal Anastomosis Systems are marketed in the United States and Europe. The PAS-Port(R) Proximal Anastomosis System is marketed in the United States, Europe and Japan. Cardica also is developing additional devices with Cook Medical to facilitate vascular closure and other surgical procedures.

Forward-Looking Statements

This press release contains "forward-looking" statements, including statements relating to the impact of Cardica's products on the field of cardiothoracic surgery, the planned launch of the Cook Vascular Access Closure Device (CVCD) in Europe and the matters described under the heading "Financial Guidance for Fiscal 2009." Any statements contained in this press release that are not historical facts may be deemed to be forward-looking statements. The words "looking," "expect," "believe" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Cardica's results to differ materially from those indicated by these forward-looking statements, including risks associated with Cardica's dependence upon the success of its current products, market acceptance of Cardica's C-Port Distal Anastomosis Systems and PAS-Port Proximal Anastomosis System, manufacturing of the C-Port Distal Anastomosis Systems and PAS-Port Proximal Anastomosis System and our suppliers, Cardica's sales, marketing and distribution strategy and capabilities, success of pre-clinical studies of and regulatory activities related to the CVCD and specialized patent foramen ovale (PFO) closure device and Cardica's need for additional funding, as well as other risks detailed from time to time in Cardica's SEC reports, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2008. Cardica does not undertake any obligation to update forward-looking statements. You are encouraged to read the Company's reports filed with the U.S. Securities and Exchange Commission, available at

~ financial statements to follow ~

Cardica, Inc.

Statements of Operations

(amounts in thousands except per share amounts)

Three months ended

September 30,

2008 2007



Product sales, net $1,560 $1,026

Development revenue 523 307

Royalty revenue 23 16

Total 2,106 1,349

Operating costs and expenses

Cost of product sales 1,110 1,013

Research and development 2,325 1,688

Selling, general and administrative 3,892 2,553

Total operating costs and expenses 7,327 5,254

Loss from operations (5,221) (3,905)

Interest income 98 270

Interest expense (30) (25)

Other income (expense) (1) 1

Net loss $(5,154) $(3,659)

Basic and diluted net loss per share $(0.33) $(0.27)

Shares used in computing basic and

diluted net loss per share 15,741 13,604

Balance Sheets

(amounts in thousands)

September 30, June 30,

2008 2008

Assets (unaudited)

Cash and investments $17,560 $23,265

Other assets 5,706 4,985

Total assets $23,266 $28,250

Liabilities and stockholders' equity

Total other current liabilities $2,327 $3,348

Deferred revenue 1,962 1,485

Total long-term liabilities 2,000 2,000

Stockholders' equity 16,977 21,417

Total liabilities and

stockholders' equity $23,266 $28,250

SOURCE Cardica, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
2. Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery
3. Cardica and Cook Sign Agreement to Expand Cook Vascular Closure Device Product Family
4. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
5. Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress
6. Cardica to Present at Jefferies 2nd Annual Healthcare Conference
7. Cardica Receives $1 Million Milestone Payment From Cook Medical for Development of Heart Defect Closure Device
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology:
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
Breaking Biology News(10 mins):